Vaccine Info

SpFN SARS-CoV-2 Vaccine

Authored by
Staff
Last reviewed
April 13, 2021
Share

SpFN SARS-CoV-2 Vaccine Description

SpFN was developed internally at Walter Reed Army Institute of Research (WRAIR).

The vaccine, currently called “SpFN” (short for “spike ferritin nanoparticle”), employs ferritin, a protein found in almost all living organisms.

By attaching a certain type of spike protein to a polymerized version of ferritin, WRAIR scientists hope the resulting vaccination dose will block COVID-19 infection.

SpFN SARS-CoV-2 Vaccine Indication

SpFN SARS-CoV-2 vaccine is indicated to prevent COVID-19 disease caused by the SARS-C0V-2 vaccine.

SpFN SARS-CoV-2 Vaccine News

April 7, 2021 - Army-developed COVID vaccine could ‘stop variants in their tracks,’ scientist says. “We have designed and positioned this platform as the next-generation vaccine, one that paves the way for a universal vaccine to protect against not only the current virus but also counter future variants, stopping them in their tracks before they can cause another pandemic,” Kayvon Modjarrad, director of Walter Reed’s emerging infectious diseases branch, said in a statement. 

January 14, 2021 - The vaccine being developed by Walter Reed, SpFN, differs from other vaccines. It uses a soccer ball-shaped protein, allowing scientists to harness the spikes of multiple coronavirus strains on 24 different faces of the protein. This unique difference may be the answer to the coronavirus mutations that have begun to circulate.

October 16, 2020 - WRAIR Announces COVID-19 Vaccine Candidate, Targets Clinical Trial Date

SpFN SARS-CoV-2 Clinical Trial

Clinical Trial NCT04784767: Phase 1 Study - SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults. Estimated Primary Completion Date: October 30, 2022.

Clinical Trials

No clinical trials found